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 CURRENTOPINION Influence of new treatment modalities on
adherence in glaucoma
Frances Meier-Gibbonsa, Michael S. Berlinb, and Marc To¨teberg-Harmsc
Purpose of review
It is well known that glaucoma patients are not adherent to their therapeutic regimens. The issue of
nonadherence is multifactorial and includes inadequate communication between doctors and patients,
resulting in significant costs associated with enhanced disease progression. Therapeutic regimens are risk
factors which often influences adherence rates. Thus, alternative treatment modalities, especially those risk
factors that do not rely on patients’ cooperation, may enable improvements in long-term outcomes of
glaucoma in patient.
Recent findings
The studies selected for this review were divided into new medications, especially advancements in
pharmaceutical approaches to treat glaucoma and new ways of delivering the medication, new surgical
methods, especially minimally invasive surgery methods for glaucoma, and new studies about adherence in
glaucoma.
Summary
Surprisingly, a very few studies on glaucoma medication or surgery addressed the concept of adherence.
However, adherence is discussed in studies which consider psychological aspects of patients or
communication issues between doctors and patients. Although these studies were performed in clinical
settings, the issue of adherence is not addressed; despite it has significant effect on long-term outpatient
care. A combination of both aspects, adherence and miscommunication, should be considered in studies.
Keywords
adherence, glaucoma diagnostic, glaucoma therapy
OUTLINE/INTRODUCTION
The rising prevalence of glaucoma worldwide invites
notonly awarenessof limitations in current therapies
but also advancements in the therapeutic options to
better enable adequate treatment to this increasing
population. According to the European Glaucoma
Society guidelines (2014), glaucoma therapy should
be easy to use, have few side-effects, and be cost
effective. It is well known that adherence is one of
the defining factors of effective glaucoma manage-
ment regimes and that glaucoma has low adherence
and low persistence rates. Several factors influence
the adherence rate of patients. Tsai [1] systematically
studiedobstacles tomedicationadherenceand found
situational and environmental factors, medication
regimens, and patient’s and provider’s factors influ-
encing adherence. Insufficient communication
between doctors and patients causes frequent
changes in therapeutic regimens. Patientshavebetter
adherence immediately before their consultations
which leads to a false impression of ‘‘adequate’’
intraocular pressure (IOP) control. Subsequent pro-
gression of visual fields and optic nerve disc changes,
however, would seem to lack explanation. Hence,
nonadherence leads to disease progression and asso-
ciated higher costs [2]. With the importance of ther-
apeutic regimens to which patients adhere, or
regimens which require less patient involvement,
inmind, the question arises as to how new therapeu-
tic modalities (new medicines, new ways of applica-
tion, and new surgical options) might influence
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adherence rates and ultimately diseasemanagement.
Thegoalof this reviewis toprovideanoverviewof the
recent literature on new therapeutic approaches in
glaucoma and their influence on patient adherence.
MATERIAL AND METHODS
Three aspects have been reviewed: new pharmaceu-
tical approaches; new surgical approaches, mini-
mally invasive surgery (MIGS) and others; and new
studies addressingadherence inglaucoma.APubMed
literature research was conducted. Included in this
review are manuscripts which have been published
between 1 July 2017 and 31 August 2018 with the
search strings: ‘glaucoma, adherence, MIGS, mini-
mally invasive glaucoma surgery, medication, treat-
ment, rhokinase inhibitors (ROCK), and NO donor’.
Only original peer-reviewed articles in Englishwhere
included. In addition, a few reviews of major interest
where added.
RESULTS
New pharmaceutical approaches to treat
glaucoma and new ways of delivering
medication
It is well known that the IOP depends mainly on
the physiological circulation of the aqueous
humor. Therefore, the two important therapeutic
approaches to reduce IOP are a reduction of aqueous
humor production or an enhancement of aqueous
humor outflow. Most of the aqueous humor exits
the eye through the trabecular or ‘conventional’
outflow system, in contrast to the uveoscleral or
‘unconventional’ pathway.
The main site of outflow resistance which leads
to an elevation of IOP is within the juxtacanalicular
portion of the trabecular meshwork and the inner
wall of Schlemm’s canal. In 2017, the first drugs
acting directly on trabecularmeshwork, ROCK, were
launched: netarsudil has a triple action; it inhibits
the Rhokinase pathway, inhibits the norephedrine
pathway and enhances outflow by lowering the
episcleral venous pressure [3,4]. Several studies con-
sidered the efficacy of ROCK. Chihara [5] and Ohta
[6] showed that Ripasudil not only lowered IOP but
also increased ocular blood flow and the density of
peripapillary vessels. Netarsudil and another ROCK,
fasudil, enabled an IOP reduction in the range of
timolol (slightly less than prostaglandin analogues),
which was ongoing for a longer time. The only side-
effect was hyperemia [7,8]. Studies combining
ROCK with prostaglandin agonists are ongoing. A
study looking at the IOP-lowering effect of ripasudil
in uveitic glaucoma found an IOP reduction of 5mm
of amedian of 23mm, but only 50%of their patients
responded to this drug [9].
A novel prostaglandin agonist which donates
nitric oxide while metabolizing was also recently
launched. Latanoprostene bunod metabolizes to
latanoprost acid (increasing uveoscleral outflow)
and butanediol mononitrate (increasing conven-
tional outflow by direct action of the released NO
at the trabecular meshwork) [10].
Other pharmacologic agents treat fibrosis at the
level of lamina cribrosa as a potential target site to
lower IOPandalso target fibrosis at theconjunctivaas
a potential treatment for preventing post filtering
surgery fibrosis [11,12]. An interesting new approach
was described by Ohia [13] and Patil [14]. H2S, a
gaseous transmitter can relax contracted vascular
smoothmuscles in severalpartsof thebody including
the eye and might be a potential drug for lowering
IOP [13,14]. Other potentially IOP lowering drugs
(adenosine receptor agents and small interfering
RNAs) are currently being studied [15,16].
Often discussed is the action of cannabis on IOP,
especially after recent legalization of this drug in
many countries, Bowen showed that smoked can-
nabis clearly reduced IOP (up to 6.6mmHg), but the
effect lasted only up to 4h [17]. This dosing require-
ment in addition to other well-known side-effects
has prevented cannabis in its current form from
becoming a treatment of choice for glaucoma. Chi-
nese herbal medicine for the treatment of primary
open-angle glaucoma is yet another interesting
option pending an examination of evidence-based
practice guidelines [18]. Traditional Chinese medi-
cine focuses on the patient’s entire body rather than
targeting specific organs. In treating glaucoma with
traditional Chinesemedicine, blood circulation, not
IOP is the main focus.
Chronic application of antiglaucomatous drops,
especially if they contain preservative agents, leads
to changes and subsequently often damage to the
KEY POINTS
 Adherence and persistence rates in the treatment of
glaucoma are relatively low compared to other chronic
diseases. Continuous patient education and checks for
glaucoma progression are mandatory requirements in
disease management.
 Significant inconsistency in the study design of MIGS
trials confounds information presented.
 We suggest as a minimal requirement for surgical
studies: wash out IOP at baseline and at the end of the
study with a minimum 2 years of follow-up. In addition,
a consensus on how to define success is needed.
Glaucoma
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ocular surface [19]. Kim [20] showed that glaucoma
patient using topical medications had a higher inci-
dence of Meibomian gland disease than controls.
One of the main problems of any ongoing applica-
tion of preservative agents is an inflammatory
response with symptoms of burning, photophobia,
and foreign body sensation. A new drug, topical
palmitoylethanolamide, showed in a study by Di
Zazzo [21] a significant improvement of the topical
surface parameters. The common method of apply-
ing antiglaucomatous medication is via topical eye
drops which often contain preservative agents,
hence in recent years, preservative-free eye drops,
which have less effect on the ocular surface, have
replaced many conventional drops.
Other means of application, which rely on less
patient adherence, would be preferable, because we
know that glaucoma patients are especially not very
successful in applying drops [22]. Another alternative
wayofdeliveringadrug is viamicrospheres, amethod
which has been examined by Tian et al. [23]. These
microspheres’ goal is to prolong the duration of
action of the drugs, thus enabling less frequent use.
New Surgical Approaches to Treat Glaucoma,
Minimally Invasive Glaucoma Surgery
Procedures
Multiple studies onMIGS procedures have been pub-
lished within the last year. The majority focus on
procedures that enhance conventional, trabecular
outflow. There have also been a number of publica-
tionsonthe fistulatingXENprocedure inwhichanab
interno implant conducts aqueous humor from the
anterior chamber to the subconjunctival space. In
addition, there are three publications describing
novel ultrasound-based cyclodestructive procedure.
iStent Trabecular Micro-bypass Stent
Ina retrospective study,Buffet et al. [24] evaluated the
24-month outcome of 63 eyes of 41 patients after
combined phaco and implantation of two iStents
(Glaukos Corporation, San Clemente, California,
USA) in mild to advanced chronic open-angle glau-
coma. IOP dropped from 16.83.0mmHg on
2.30.9 medications by 10% at 2 years [24]. At the
same timemedicationswere reducedby40% [24].No
severe device-related adverse events were noted [24].
A minimal hyphema occurred in 3% of the patients
which resolved in the first week [24].
XEN45 Gel Stent
Widder et al. followed-up 261 eyes after XEN45 Gel
Stent (Allergan plc, Irvine, California, USA)
implantation for 8.5 months [25
&
]. IOP was lowered
from 24.3mmHg (SD 6.6) to 16.8mmHg (SD 7.6),
and the hypotensive medications were reduced
from 2.6 (SD 1.1) to 0.2 (SD 0.7) [25
&
]. Needling rate
was not neglectable with 34%. The group found a
higher success rate in pseudophakic eyes, compared
to combined surgery or surgery in phakic eyes [25
&
].
Hohberger et al. [26] found a success rate of 47% in
XEN Gel stent alone (n¼81) compared to 53% in
combined XEN and phaco (n¼30) with 6months of
follow-up. Success was defined as IOP less than
18mmHg without local antiglaucomatous therapy
or further surgical interventions [26]. In a singlearm,
open-label, multicenter clinical study, Grover et al.
followed 65 eyes for 12 months [27]. All eyes were
treated with mitomycin. Success was achieved in
75% of the cases defined as percentage of eyes
achieving more than 20% IOP reduction from base-
line on the same or fewer medications at month 12
[27]. To achieve this goal, a needling was required in
32.3% of the patients (9.2% had two needlings and
2% had three needlings) [27]. Mean IOP reduction
from baseline was 9.1mmHg and number of med-
ications was reduced from 3.5 to 1.7 [27]. De Gre-
gorio et al. [28] published a nonrandomized,
prospective study of 41 eyes of 33 patients of com-
bined phaco and XEN45 Gel Stent implantation.
Complete success rate was 80% defined as a postop-
erative IOP more than 6 and less than 17mmHg
without glaucoma medications [28]. IOP was
22.53.7mmHg on 2.50.9 medication classes
at baseline and was reduced at 12 months to
13.12.4mmHg (42%) on 0.40.8 medication
classes [28].
Microhook ab interno trabeculotomy
A retrospective case-series was published of com-
bined phaco and ab interno trabeculotomy with a
microhook of 68 eyes of 48 patients in a Japanese
population [29]. Mean preoperative IOP decreased
from 16.42.9mmHg on 2.41.2 antiglaucoma
medications to 11.84.5mmHg on 2.11.0mmHg
mmHg at 9.5months postoperatively [29]. Hyphema
was the most common postoperative complication
[29].
Gonioscopy-assisted Transluminal
Trabeculotomy
Rahmatnejad et al. [30
&
] retrospectively reported
outcomes of 66 cases of gonioscopy-assisted trans-
luminal trabeculotomy with an iTrack microcath-
eter (Ellex iScience Inc., Fremont, California, USA)
in open-angle glaucoma. Follow-up ranged from 3
to 30 months with an average of 11.9 months [30
&
].
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Mean IOP was reduced from 26.19.9mmHg on
3.11.1 medications to 14.64.7mmHg on
1.20.9 medications at 12 months [30&]. Success
rate (defined as IOP reduction >20% from baseline
or IOP between 5 and 21mmHg, and no need for
further glaucoma surgery) was 63% [30
&
]. Success
rate was higher in Whites (69%) versus Blacks (42%)
[30
&
]. The main postop complication was hyphema,
which was present in 38% of the cases at 1 week and
6% at 1 month [30
&
].
Ab interno Trabeculotomy with the
Trabectome
Kostanyan et al. [31] published a comparison study
of 29matched Baerveldt glaucoma drainage implant
cases to 30 cases after ab interno trabeculectomy
with the trabectome [31]. The primary outcome
measures were IOP, number of glaucoma medica-
tions, and a Glaucoma Index score, which reflected
glaucoma severity based on visual field, the number
of preoperative medications, and preoperative IOP
[31]. Success, defined as an IOP less than 21mmHg,
more than 20% reduction, and no reoperation, was
achieved in 50% in the ab interno trabeculectomy
with the trabectome group versus 52% in the Baer-
veldt glaucoma drainage implant group at 2.5 years
[31]. Both groups had similar IOP after 30 months
(15mmHg) [31].
Ultrasound Cyclo Plasty
Ultrasound cyclo plasty (UCP) is a nonincisional
technique to reduce IOP in glaucoma by coagulation
of ciliary body (EyeOP1, Eye Tech Care, Rillieux-la-
Pape, France) [32]. The procedure is performed in
the operating room under peribulbar anesthesia
[32]. A ‘coupling cone’ is placed in contact with
the eye (available in three sizes: 11, 12, and
13mm in diameter) and ultrasound energy is deliv-
ered by six piezoelectric transducers focused on the
ciliary body [32]. Recently, a multicentre prospec-
tive study from Italy with a 1-year follow-up was
published [33]. In total, 49 eyes from 47 patients
were included [33]. Mean IOP decreased from
27.79.2 to 19.86.9 mmHg (P<0.001), and
the mean number of hypotensive medication
decreased from 3.2 to 2.3 simultaneously
(P<0.05) [33]. Qualified success rate was 51% and
complete success rate was 43% [33]. Criteria of
qualified success were IOP reduction to at least
20% and more than 5mmHg without adjunctive
hypotensive medication, whereas complete success
was as above and IOP less than 21mmHg [33].
Prospectively, De Gregorio et al. [34] investigated
40 eyes of 40 patients for 1 year with a diagnosis of
primary or secondary uncontrolled glaucoma under
maximal tolerated medical therapy. Complete suc-
cess was defined as a final IOP more than 5 mmHg
and 21mmHg or less without hypotensive medica-
tion adjunction and no major or vision-threatening
complications [34]. A retreatment after 4 months
was allowed whenever IOP wasmore than 21mmHg
[34]. Baseline IOP was 32.59.9 mmHg.(43) IOP
reduction was 27.8% at 4 months [34]. Retreatment
was required in every second eye and 30% of the
eyes required three UCP procedures within 1 year
[34]. Overall success at 12 months was 85% [34].
DISCUSSION
Few studies have been published on MIGS proce-
dures in the last 12 months. The majority were on
the XEN45 Gel stent and UCP. In addition, signifi-
cant inconsistency in the study design ofMIGS trials
confounds information presented. As a minimal
requirement, the following study design is suggested
by the Federal Drug and Food administration: wash
out IOP at baseline and at the end of the study and at
least 2 years of follow-up. In addition, a consensus
on how to define success is needed. Many studies
adapted criteria from the tube versus trabeculec-
tomy study, that is, IOP of 21mmHg or less and
IOP reduction more than 20% from baseline [35].
However, we believe a pressure of 21mmHg or less
would not be considered a successful outcome in a
clinical setting in most glaucoma patients. Much
more strict criteria are needed, for example, IOP of
less than or equal to 18 or 16mmHg to define
clinically relevant success. For future studies, we
strongly suggest that standardized study designs
and outcome criteria are adopted to better enable
the evaluation of MIGS procedures and to
enable comparisons.
Glaucoma is unique in that adherence and per-
sistence rates in the treatment of glaucoma are
relatively low compared to other chronic diseases
which require lifelong therapeutic interventions
[36]. Self-reported adherence rates tend to be lower
than actually measured adherence rates. However,
one study tested a wireless monitoring device com-
pared to self-reported activity via a questionnaire
[37]. Interestingly, the self-reported median adher-
ence was 82% and dropped after 30 days, but was
higher than the objectively measured adherence (56
versus 52.2%). The authors confirmed that the self-
reported and the objectively measured adherence
rate differed and suggested considering implemen-
tation of such a measuring device in daily practice.
The question often arises whether or not increasing
patient understanding of his or her disease and
about their therapy improves adherence. Fiscella
Glaucoma
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[38
&
] looked at over 23000 patients and found no
improvement in adherence despite intensive educa-
tion by means of mailings. This is understandable
considering the study of Anbesse [39] in which the
most often cited reasons for nonadherence are: for-
getfulness, being busy, and being away from home.
It is very important to incorporate a therapeutic
program which is easy to use and easy to integrate
into the daily lives of patients. Young patients tend
to show lower adherence, in spite of having greater
access to electronic devices. They manage online
information without a doctor’s help, but this does
not seem to improve their adherence [40]. Knowing
that patients with a reduced visual quality of life at
the beginning of their disease show a reduced adher-
ence when first measured, we should improve their
education about their disease which leads to
improved adherence to their therapeutic regimens
[41]. An important step to improve adherence is as
simple as providing instructions about eye drop
instillation techniques [42].
CONCLUSION
Adherence and compliance are still a problem in
management of chronic diseases as glaucoma. Thus,
continuous education of patients is crucial to
improve adherence and compliance.
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